With about $15.3 million in cash and marketable securities as of the third quarter's end - enough to last through the first half of this year - Iomai Corp. is getting a welcome revenue shot in the arm for its dose-sparing skin patch: $14.5 million from the government, as part of allocations in the pandemic-influenza program. (BioWorld Today)